Mohammed Abbas Baghdadi on Muck Rack

Mohammed Abbas Baghdadi

As seen in: eCancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mohammed Abbas

Contact Mohammed Abbas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with

|
By Jamal Zekri, Mohammed Abbas Baghdadi, Refaei Belal Ibrahim, Abdelrazak Meliti
| eCancer Verified
Category Sub-category Article type Volume Abstract | Full Article | PDF Research Background: Oral capecitabine in combination with intravenous oxaliplatin (XELOX) or irinotecan (XELIRI) are acceptable substitutions to fully intravenous regimens. Biweekly (as opposed to weekly) cetuximab is more convenient when combined with biweekly chemotherapy.
Open in Who Shared Issue with article?

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with

|
By Jamal Zekri, Mohammed Abbas Baghdadi, Refaei Belal Ibrahim, Abdelrazak Meliti
| eCancer Verified
How likely is this article to improve patient care in your region? Is reading this article likely to improve your clinical practice? How likely are you to recommend this article to a colleague?
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified